CRISPR Therapeutics wins FDA pediatric approval for Casgevy, boosting market potential and pipeline upside despite slow uptake. Click here to read more.
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
The opportunity is enormous, but uncertainty remains.
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high ...
The CRISPR-based drug development platforms market capitalizes on the growing demand for precision medicine and gene editing advancements, especially in oncology. Opportunities lie in enhanced drug ...
6d
CRISPR Therapeutics AG vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
From gene-editing breakthroughs to blockbuster cystic fibrosis drugs, these two industry leaders present sharply contrasting ...
The use of genome editing in early embryos has pulled back the curtain on the role of one of the key genes that orchestrates ...
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.
New Scientist on MSN
I’m the first person whose life was saved by CRISPR base editing
When standard leukaemia treatments failed, 13-year-old Alyssa Tapley was told she had only weeks left – but then she was ...
A team of researchers led by Professor Akitsu Hotta (Department of Clinical Application) developed a comprehensive framework ...
Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...
In a rapidly changing climate landscape, the plants we rely on for food, textiles and more face a multitude of challenges, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results